Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
复制标题
DOI：
10.1016/j.humpath.2011.05.023
复制
发表时间：
2012-04-01
期刊：
影响因子：
3.3
通讯作者：
Davidson, Ben
中科院分区：
文献类型：
--
作者：
Brenne, Kjersti;Nymoen, Dag Andre;Davidson, Ben
先前使用基因表达阵列显示，与恶性间皮瘤相比，EHF（Ets 同源因子）基因在卵巢/原发性腹膜浆液性癌中过度表达。本研究的目的是在更大系列的 mRNA 水平上验证这一发现。我们使用定量实时聚合酶链反应分析了 EHF 在 98 例卵巢浆液性癌积液、23 例恶性间皮瘤标本（20 例积液、3 例手术标本）和 28 例原发性卵巢浆液性癌中的诊断作用。另外还研究了卵巢癌中 EHF 的表达水平与临床病理参数和生存的关系。实时定量聚合酶链反应分析显示，与恶性间皮瘤渗出液相比，卵巢癌渗出液和原发性卵巢癌中 EHF mRNA 的表达显着升高（两者 P < .001）。与这种癌症的积液相比，原发性卵巢癌中的 EHF mRNA 表达更高 (P < .001)。在对所有积液患者的单变量分析中，较高的 EHF mRNA 水平与较短的无进展生存期趋势相关 (P = .066)，这在对 45 名初诊化疗前积液患者的分析中变得显着 (P = .01)。在 Cox 多变量分析中，EHF mRNA 表达是所有患者和初次诊断化疗前积液患者无进展生存期较差的独立预测因子（分别为 P = .033 和 P = .009）。 EHF mRNA 水平可区分卵巢癌和恶性间皮瘤，因此在这种情况下可能具有诊断价值。 EHF 可能是卵巢癌的一种新的预后标志物。 2012 爱思唯尔公司。保留所有权利。
The EHF(Ets homologous factor) gene was previously shown to be overexpressed in ovarian/primary peritoneal serous carcinoma compared to malignant mesothelioma using gene expression arrays. The objective of this study was to validate this finding at the mRNA level in a larger series. We analyzed the diagnostic role of EHF in 98 ovarian serous carcinoma effusions, 23 malignant mesothelioma specimens (20 effusions, 3 surgical specimens), and 28 primary ovarian serous carcinomas using quantitative real-time polymerase chain reaction. Expression levels of EHF in ovarian carcinoma were additionally investigated for association with clinicopathologic parameters and survival. Quantitative real-time polymerase chain reaction analysis showed significantly higher expression of EHF mRNA in ovarian carcinoma effusions and in primary ovarian carcinoma compared to malignant mesothelioma effusions (P < .001 for both). EHF mRNA expression was additionally higher in primary ovarian carcinomas compared to effusions of this cancer (P < .001). In univariate analysis for all patients with effusions, higher EHF mRNA levels were associated with a trend for shorter progression-free survival (P = .066), which became significant in analysis of 45 patients with primary diagnosis pre-chemotherapy effusions (P = .01). In Cox multivariate analysis, EHF mRNA expression was an independent predictor of poor progression-free survival for all patients and patients with primary diagnosis pre-chemotherapy effusions (P = .033 and P = .009, respectively). EHF mRNA levels differentiate ovarian carcinoma from malignant mesothelioma and may thus be of diagnostic value in this setting. EHF may be a novel prognostic marker in ovarian carcinoma. 2012 Elsevier Inc. All rights reserved.